Digital Health Industry News

A collection of Digital Health latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

forbes.com - Colin Lawlor - ​Sleep Data As Healthcare's Next Trust Battleground: Considerations For Industry Leaders
​Sleep Data As Healthcare's Next Trust Battleground: Considerations For Industry Leaders
Forbes

Colin Lawlor, CEO, SleepScore Labs. For most of my career, sleep sat in an odd place in health. Doctors ignored it or told patients to “sleep off” their ailments. Many wellness brands talked about it, but sleep was still treated as an…

forbes.com - Jiang Li - The Hidden Costs Of Signing Multiple Vendors For One Clinical Trial
The Hidden Costs Of Signing Multiple Vendors For One Clinical Trial
Forbes

Jiang Li, Ph.D., is the Founder and CEO of Vivalink, Inc. Many sponsors building wearable data workflows into clinical trials have gotten comfortable signing four or five vendors for a single study: a sensor company, an algorithm company, a cloud…

fool.com - John Ballard - Butterfly Network CEO Joseph Devivo Sells 68,346 Shares
Butterfly Network CEO Joseph Devivo Sells 68,346 Shares
The Motley Fool

Joseph Devivo, President & CEO of Butterfly Network (BFLY -6.24%), sold 68,346 shares of Class A Common Stock on Aug. 10, 2026, according to a SEC Form 4 filing. MetricValueTransaction value~$684,143Shares sold (directly held)68,346Post-transaction…

fool.com - Motley Fool Transcribing - Inogen (INGN) Q2 2026 Earnings Call Transcript
Inogen (INGN) Q2 2026 Earnings Call Transcript
The Motley Fool

Thursday, Aug. 6, 2026 at 5:00 p.m. ET SVP of Investor Relations and Strategic Planning-Lorna Williams President and CEO-Kevin Smith CFO-Jason Richardson Chief Operating Officer-Andy Reding Total Revenue -- $95.1 million, representing 3% growth…

marketbeat.com - GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory Meeting
GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory Meeting
MarketBeat

Small-Cap Standouts: These 3 Stocks Rose Over 300% in 2025 GRAIL NASDAQ: GRAL Chief Financial Officer Aaron Freidin said the company's Galleri multi-cancer early detection test recorded strong first-half growth as it expanded distribution through…

fool.com - Motley Fool Transcribing - ResMed (RMD) Q4 2026 Earnings Call Transcript
ResMed (RMD) Q4 2026 Earnings Call Transcript
The Motley Fool

Thursday, Aug. 6, 2026 at 4:30 p.m. ET Chief Investor Relations Officer-Salli Schwartz Chairman and Chief Executive Officer-Mick Farrell Chief Financial Officer-Aaron Bloomer Revenue -- $1.46 billion, reflecting 9% growth year over year or 8% in…

bbc.co.uk - Osmond Chia - Selena Gomez sued for alleged fraud over mental health company
Selena Gomez sued for alleged fraud over mental health company
BBC

Osmond Chia, Business reporter and Lucy Hooker, Business Reporter Hollywood actress and singer Selena Gomez is being sued by five investors who backed Wondermind Global, a mental health business she founded with her mother. Shareholders are…

bbc.co.uk - Osmond Chia - Selena Gomez sued for alleged fraud over mental health company
Selena Gomez sued for alleged fraud over mental health company
BBC

Hollywood actress and singer Selena Gomez is being sued by five investors who backed Wondermind Global, a mental health business she founded with her mother. Shareholders are claiming the pop star failed to fulfil promises that she would be…

marketbeat.com - JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Omada Health (NASDAQ:OMDA) Stock
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Omada Health (NASDAQ:OMDA) Stock
MarketBeat

Omada Health (NASDAQ:OMDA - Get Free Report) had its target price lifted by equities research analysts at JPMorgan Chase & Co. from $26.00 to $30.00 in a research report issued on Friday, Benzinga reports. The brokerage currently has an…

marketbeat.com - OptimizeRx (NASDAQ:OPRX) Stock Price Expected to Rise, Citizens Jmp Analyst Says
OptimizeRx (NASDAQ:OPRX) Stock Price Expected to Rise, Citizens Jmp Analyst Says
MarketBeat

OptimizeRx (NASDAQ:OPRX - Get Free Report) had its target price increased by investment analysts at Citizens Jmp from $9.00 to $11.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage currently has a…

marketbeat.com - Citizens Jmp Raises Omada Health (NASDAQ:OMDA) Price Target to $32.00
Citizens Jmp Raises Omada Health (NASDAQ:OMDA) Price Target to $32.00
MarketBeat

Omada Health (NASDAQ:OMDA - Get Free Report) had its price objective hoisted by Citizens Jmp from $27.00 to $32.00 in a report issued on Friday, Benzinga reports. The brokerage currently has a 'market outperform' rating on the stock. Citizens Jmp's…

marketbeat.com - Bank of New York Mellon Corp Has $951,000 Position in Omada Health, Inc. $OMDA
Bank of New York Mellon Corp Has $951,000 Position in Omada Health, Inc. $OMDA
MarketBeat

Bank of New York Mellon Corp raised its position in Omada Health, Inc. (NASDAQ:OMDA - Free Report) by 284.5% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 75,681 shares of the company's…

marketbeat.com - Renaissance Technologies LLC Has $1.36 Million Stock Position in OptimizeRx Corp. $OPRX
Renaissance Technologies LLC Has $1.36 Million Stock Position in OptimizeRx Corp. $OPRX
MarketBeat

Renaissance Technologies LLC increased its stake in OptimizeRx Corp. (NASDAQ:OPRX - Free Report) by 633.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor…

fool.com - Motley Fool Transcribing - JD.com (JD) Q2 2026 Earnings Call Transcript
JD.com (JD) Q2 2026 Earnings Call Transcript
The Motley Fool

Thursday, Aug. 13, 2026 at 8 a.m. ET Head of Investor Relations - Sean Zhang Chief Executive Officer - Sandy Xu Chief Financial Officer - Ian Shan Net Revenues -- RMB 346.4 billion, a 2.9% decrease year over year primarily due to a high base effect…

theguardian.com - Bala Subramaniam - I'm a neuroscientist. Here's why our brains need pop concerts | Bala Subramaniam
I'm a neuroscientist. Here's why our brains need pop concerts | Bala Subramaniam
The Guardian

Three years ago, I agreed to accompany my children to a Nick Jonas concert. The appeal of the Jonas Brothers, and in this case only one of them, was unfamiliar territory. The concert happened to land on a particularly inconvenient day. As I…

Receive a Daily briefing on Digital Health Industry News

Get Started